Louisiana chucks Risperdal settlement

Share this article:

A Louisiana appeals court has overturned a Risperdal settlement to Johnson & Johnson's advantage. Bloomberg reports that the court tossed a $257.7 million deceptive marketing verdict, saying prosecutors failed to provide enough evidence of wrongdoing.

Despite the local win for J&J, Louisiana is just a minor point in a bigger marketing tangle, which includes allegations from the Department of Justice that the drugmaker's marketing strategies triggered fraudulent government payments for the anti-psychotic, and allegations of tying speaker fees to prescription rates, among others.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.